Target intelligence / Profile preview

T cell receptor beta joining 2-7 (TRBJ2-7)

Target
TRBJ2-7
Molecular classification
Other (Immunoglobulin gene segment)
01

Overview

T cell receptor beta joining 2-7 (TRBJ2-7) is one of several joining (J) gene segments in the TCR beta locus. During T cell development, the TCR beta chain is assembled via somatic recombination, joining one variable (V), one diversity (D), and one joining (J) gene segment to form the antigen-binding domain. TRBJ2-7 encodes a portion of the complementarity-determining region 3 (CDR3) in the beta chain, which is the primary region for antigen contact. The collective diversity generated by different V(D)J combinations enables the adaptive immune system to recognize a vast array of antigens. However, the TRBJ2-7 segment itself is not a protein, receptor, or enzyme but a DNA sequence that contributes to a segment of the T cell receptor. Key clarifications: - TRBJ2-7 is not a protein or functional receptor: It does not exist as an independent molecular entity at the protein or cell-surface level; its significance is in genomic recombination for TCR diversity. - Therapeutic intervention targets the T cell receptor complex or its signaling—not this individual segment. For drug and antibody development focus, one should target the T cell receptor complex or pathway components (e.g., CD3, CD28, signal transduction proteins), not individual V, D, or J segments such as TRBJ2-7.

Other names
TRBJ2-7TRBJ27TCRBJ2S7
02

Biological functions

Generation of T cell receptor diversityAdaptive immune response
03

Disease associations

Other (Alterations in TCR repertoire can be linked to immune disorders or lymphoma clonality, but this is an indirect association, not a direct role)

Beyond the preview

Go deeper on T cell receptor beta joining 2-7 (TRBJ2-7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 2-7 (TRBJ2-7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call